Gilead has struck a deal to buy Tubulis for $3.15 billion upfront, securing an ADC candidate that is...
Gilead pays $3.1B for Tubulis to bolster oncology ADC pipeline
Gilead has struck a deal to buy Tubulis for $3.15 billion upfront, securing an ADC candidate that is racing toward pivotal trials.
Author: Fierce Biotech
Read Original Article